Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.

An Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator has been described recently, and it has been hypothesized that this polymorphism may predict risk of coronary thrombosis. In a prospective cohort of nearly 15,000 apparently healthy men, presence of an Alu-repeat insertion/deletion (I/D) polymorphism in the gene coding for tissue-type plasminogen activator was determined among 369 study participants who subsequently suffered a first myocardial infarction (cases) and among a group of 369 age- and smoking-matched study participants who remained free of reported cardiovascular disease during follow-up (controls). The distributions of the II, DI, and DD genotypes of the tissue-type plasminogen activator polymorphism among men who subsequently suffered myocardial infarction (0.30, 0.50, 0.21) were virtually identical to those who remained free of disease (0.29, 0.50, 0.21; P = .9). There was no evidence of association between the Alu insertion polymorphism and risks of future myocardial infarction in models assuming either allelic recessive (relative risk, 1.05; 95% confidence interval, 0.8 to 1.4, P = .8) or allelic dominant (relative risk, 1.04; 95% confidence interval, 0.7 to 1.5, P = .8) modes of inheritance, nor were associations found in analyses stratified by age, family history, hypercholesterolemia, or the presence of other risk factors for premature coronary disease. Multivariate analysis had no important effects on these relationships. In this cohort of middle-aged US men, the presence of the insertion allele of the Alu-repeat polymorphism of the tissue-type plasminogen activator gene is not associated with future risks of myocardial infarction.

[1]  P. Ridker,et al.  Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. , 1997, Circulation.

[2]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[3]  D. Collen,et al.  Impaired fibrinolysis and the risk for coronary heart disease. , 1996, Circulation.

[4]  A. Castelnuovo,et al.  Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI) , 1996 .

[5]  M. Bots,et al.  Fibrinolytic capacity and risk of myocardial infarction , 1996 .

[6]  N L Geller,et al.  Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. , 1995, Circulation.

[7]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[8]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[9]  G. Lowe,et al.  Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population , 1995 .

[10]  P. de Knijff,et al.  Alu-repeat Polymorphism in the Tissue-Type Plasminogen Activator (tPA) Gene Does not Affect Basal Endothelial tPA Synthesis , 1995, Thrombosis and Haemostasis.

[11]  P. Ridker,et al.  Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. , 1994, JAMA.

[12]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[13]  A. Crawford,et al.  Familial thrombophilia, hypofibrinolysis, and high lipoprotein(a): Pathophysiologic etiologies of legg-perthes , 1994 .

[14]  S. Humphries.  The genetic contribution to the risk of thrombosis and cardiovascular disease. , 1994, Trends in cardiovascular medicine.

[15]  J. Jansson,et al.  Predictive Value of Tissue Plasminogen Activator Mass Concentration on Long‐term Mortalit in Patients With Coronary Artery Disease A 7‐Year Follow‐up , 1993, Circulation.

[16]  T. Meade,et al.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study , 1993, The Lancet.

[17]  L. Guize,et al.  Haemostatic Variables and Menopausal Status: Influence of Hormone Replacement Therapy , 1993, Thrombosis and Haemostasis.

[18]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[19]  R R Wing,et al.  Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  B. Sobel,et al.  Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients , 1993, Diabetes.

[21]  K. Matthews,et al.  Hemostatic factors according to menopausal status and use of hormone replacement therapy. , 1992, Annals of epidemiology.

[22]  F. Andreotti,et al.  Circadian variation of fibrinolytic activity in blood. , 1991, Chronobiology international.

[23]  W. Chandler,et al.  Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). , 1989, Circulation.

[24]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[25]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[26]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .